May 2, 2019 • 12:00 pm EDT Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
May 1, 2019 • 8:05 am EDT Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
Apr 18, 2019 • 8:05 am EDT Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA
Mar 12, 2019 • 7:00 am EDT Corbus Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Clinical Updates
Mar 11, 2019 • 8:35 am EDT Corbus Pharmaceuticals to Present at the Oppenheimer 29th Annual Healthcare Conference
Mar 7, 2019 • 8:00 am EST Corbus Pharmaceuticals to Announce Full-Year 2018 Operational and Financial Results on March 12, 2019
Mar 4, 2019 • 9:15 am EST Corbus Pharmaceuticals Announces Appointment of Craig Millian as Chief Commercial Officer
Jan 30, 2019 • 7:30 am EST Corbus Pharmaceuticals Announces Closing of $40 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares